3results about How to "Inhibitory function" patented technology

This invention discloses the application of ITPRIPL1 as a biomarker for the diagnosis or prognosis of gastric cancer. Database analysis revealed high expression of ITPRIPL1 in gastric cancer patients. Immunohistochemical staining of samples from clinically diagnosed gastric cancer patients further validated its high expression in gastric cancer tumor cells, with higher ITPRIPL1 expression levels observed in lower-differentiated tumor tissues. This invention provides a novel biomarker for the diagnosis and prognosis of gastric cancer, offering new ideas and directions for immunotherapy of gastric cancer.

The application provides a battery and a power utilization device, which comprise a negative electrode sheet, the negative electrode sheet comprises a nickel element, the mass content of the nickel element is X, and the volume median particle size of the negative electrode active material is H; an electrolyte comprises a first additive, a second additive and a third additive, the mass percentage content of the first additive is A, the mass percentage content of the second additive is B, and the mass percentage content of the third additive is C; the values of A, B, C, H and X satisfy the following conditions: 0.001 <= (A+B) / X <= 0.83; 0.2 <= (A+B+C) / H <= 3.06; 0.18 <= C / (A+B) <= 3.2; in the application, (A+B) / X ensures the balance between the total amount of the additive and the pollution degree for the nickel impurity interface; (A+B+C) / H realizes the matching between the chemical protection of the additive and the negative electrode particle size; C / (A+B) balances the proportion of the basic film forming and the interface stable protection; the interface side reaction and the SEI film instability problem caused by the migration of the nickel element dissolution are effectively inhibited, so that the battery realizes the optimal balance between the thermal shock safety, the low-temperature cycle and the high-temperature cycle performance.

The invention opens up a brand new application field of the composition formed by the diosmin and the PD-1 inhibitor, and provides a potential, effective, safe and economical new treatment scheme for gastric cancer patients, especially patients intolerant or drug-resistant to traditional chemotherapy. The invention proves that diosmin can effectively and specifically inhibit the activity of NUAK1 kinase and further inhibit a Wnt / beta-catenin signal channel at the downstream of the NUAK1 kinase. The effect is directly shown as that the protein expression levels of key transcription factors TCF4 and LEF1 are remarkably reduced, so that the function of diosmin serving as a novel NUAK1 inhibitor is proved on the molecular mechanism level, and the tumor inhibition effect of the composition formed by diosmin and the PD-1 inhibitor is remarkably superior to that of the PD-1 inhibitor.